ramg, hope the Lonsurf gives you good results to get you out of the present situation. It's very logic from your doctor to recommend that now. BUT the trial he's proposing you is immunotherapy (that you haven't had until now), a very good combination.
The drug is PDR001 (not PDR101). It's just the anti PD-1 from Novartis (similar to Opdivo and Keytruda). You see less data/ no data on it because that company got later in the "race", that is all. So they are making their bets on combinations. And all of the ones in this trial are very good ones:
The trial is
"A Study of PDR001 in Combination with CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
*Arms specific for CRC (only MSS)
*Combination: PD-1 checkpoint inhibitor (PDR001) + other four agents with immunomodulatory activity (one of them)https://clinicaltrials.gov/ct2/show/NCT02900664
*_Four_arms_for_CRC. Non randomized. According to tumour characteristics/mutations, CRC patients are assigned to one of the following combinations:
** aPD-1 +canakinumab (Ilaris ; anti IL-1β (monoclonal antibody targeted to interleukin-1 beta), FDA approved anti-Inflammatory, injection)
** aPD-1 + CJM112 (monoclonal antibody targeted to interleukin-17)
** aPD-1 +trametinib (Mekinist; MEK inhibitor, FDA approved, oral)
** aPD-1 + EGF816 (mutant-selective EGFR tyrosine kinase inhibitor; oral)
* Tennessee, Texas, Belgium, Canada, Singapore, Spain
(I put in bold the trial your doc was thinking to include you in).
Other trial that you have in Singapore is other with the same drug, in other combination:
"Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas"
*Combination (PD-1 checkpoint inhibitor (PDR001) + anti-GITR GWN323 ) and monotherapy (anti-GITR alone)
* Illinois (U. Chicago), Massachusetts (Dana Farber), New York (MSK), Texas (MD Anderson), Canada, Israel, Singapore, Spain
Both trials have a lot of rationale, in its mechanism of action, for CRC.